Sapience Therapeutics to Showcase Clinical and Biomarker Data from ST101 Phase 2 Study in GBM at ASCO 2024

-Oral presentation on June 1, 2024- TARRYTOWN, N.Y., May 23, 2024 /PRNewswire/ — Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today…